
Zoetis (ZTS) Stock
Global leader in animal health medicines and vaccines. Here's the price, business snapshot, and what's worth knowing about Zoetis in November 2026.
Zoetis Inc. (ZTS) is a global leader in animal health, developing, manufacturing and commercialising medicines, vaccines and diagnostics for livestock and companion animals. With a market capitalisation of about $64.7bn, the company benefits from steady, recurring demand driven by pet ownership trends, livestock productivity needs and veterinary services growth across developed and emerging markets. Zoetis' strength lies in a diversified product portfolio, a broad geographic footprint and ongoing investment in R&D and targeted acquisitions to expand its pipeline. Investors should note potential advantages — predictable cash flows, margin resilience and dividend capacity — alongside risks such as regulatory scrutiny, pricing pressures, disease outbreaks and currency exposure. Zoetis may suit investors seeking exposure to defensive growth within healthcare, but it is important to assess valuation, portfolio fit and risk tolerance. This information is educational only and not personalised investment advice; values can rise or fall and past performance is not a guarantee of future returns.
Why It’s Moving

Zoetis Secures USDA License for New Poultry Vaccine, Expanding Portfolio
- The newly licensed Poulvac® Procerta® HVT-ND-ILT is a vector vaccine that combines three disease targets into a single product for poultry.
- This approval expands the toolkit available to poultry veterinarians and producers, reinforcing Zoetis' leadership in the animal health sector.
- The license marks a key step in Zoetis' continued investment in innovative solutions for disease protection in livestock.

Zoetis Secures USDA License for New Poultry Vaccine, Expanding Portfolio
- The newly licensed Poulvac® Procerta® HVT-ND-ILT is a vector vaccine that combines three disease targets into a single product for poultry.
- This approval expands the toolkit available to poultry veterinarians and producers, reinforcing Zoetis' leadership in the animal health sector.
- The license marks a key step in Zoetis' continued investment in innovative solutions for disease protection in livestock.
Six-Month Growth Performance
When is the next earnings date for ZOETIS INC (ZTS)?
No confirmed upcoming earnings date has been announced for Zoetis as of November 16, 2026. Based on the company's historical reporting pattern, which typically occurs approximately three months after the previous quarter's release, the next report is expected in February 2027. This anticipated filing will cover the fourth quarter and full-year results for fiscal 2026.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Zoetis' stock with a target price of $152.81, indicating potential growth.
Financial Health
Zoetis is performing well with strong profits and cash flow, indicating solid financial health.
Dividend
Zoetis Inc's dividend yield of 2.49% indicates a moderate return for investors seeking dividends. If you invested $1000 you would be paid $24.90 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Steady demand drivers
Rising pet ownership and livestock productivity needs can support predictable revenue, though sales can vary with animal health trends and outbreaks.
Global footprint
A wide geographic reach exposes Zoetis to growth in emerging markets, but also brings currency and regulatory risk across regions.
R&D and pipeline
Ongoing investment in R&D and selective acquisitions fuels future products, yet new launches carry execution and approval risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.